NCT00419770View on ClinicalTrials.gov

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2010

Conditions
Mucormycosis
Interventions
DRUG

deferasirox

20 mg/kg enterally per day

DRUG

Placebo

DRUG

Liposomal amphotericin B

Trial Locations (7)

27710

Duke University, Durham

33136

University of Miami, Miami

44304

Summa Health Systems, Akron

77030

MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

94143

UCSF, San Francisco

98109

Fred Hutchinson Cancer Research Center, Seattle

Sponsors
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER